Use of bacterial phage associated lysing enzymes for treating upper respiratory illnesses
View Patent ↗The present invention relates to an oral delivery system containing a bacteriophage associated lysin enzyme for the treatment of [ Streptococcus pneumoniae and] Hemophilus influenzae sinus/nasal infections.
1. A method for treating Hemophilus influenza infections of an upper respiratory tract, wherein the method comprises delivering to the mouth, throat or nasal passages a composition comprising:
(i) an effective amount of at least one lytic enzyme genetically coded for by a bacteriophage specific for said Hemophilus influenza , said at least one lytic enzyme having the ability to specifically digest a cell wall of said Hemophilus influenza ; and
ii) a carrier for delivering said enzyme to a mouth, throat, or nasal passage.
2. The method according to claim 1 , wherein said carrier is candy, chewing gum, lozenge, troche, tablet, a powder, an aerosol, a liquid and a liquid spray.
3. The method according to claim 1 , wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.
4. The method according to claim 3 , wherein the buffer maintains the pH of the composition at the range between about 5.5 and about 7.5.
5. The method according to claim 3 , wherein said buffer comprises a reducing reagent.
6. The method according to claim 5 , wherein said reducing reagent is dithiothreitol.
7. The method according to claim 3 , wherein said buffer comprises a metal chelating reagent.
8. The method according to claim 7 , wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.
9. The method according to claim 3 , wherein said buffer is a citrate-phosphate buffer.
10. The method according to claim 1 , further comprising a bactericidal or bacteriostatic agent as a preservative.
11. The method according to claim 1 , wherein said at least one lytic enzyme is lyophilized.
12. The method according to claim 1 , wherein said carrier further comprises a sweetener.
13. The method according claim 1 , further comprising administering a concentration of about 100 to about 100,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.
14. The method according to claim 13 , further comprising administering the concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.